Kiniksa Pharmaceuticals International, plc
KNSA
$31.98
$1.725.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 146.82% | -295.95% | -406.68% | -35.51% | -104.42% |
| Total Depreciation and Amortization | -26.34% | -28.81% | -27.60% | -23.64% | -11.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.00% | 3,951.85% | 1,047.21% | -10.65% | 118.50% |
| Change in Net Operating Assets | 355.76% | 84.42% | 1,737.70% | 101.67% | 143.91% |
| Cash from Operations | 119.75% | 104.25% | 93.14% | 532.46% | -28.26% |
| Capital Expenditure | -192.95% | -53.68% | -113.08% | -233.33% | -225.00% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | 150.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 108.23% | -214.82% | 228.87% | 25.99% | -86.12% |
| Cash from Investing | 107.27% | -216.25% | 227.46% | 25.83% | -86.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 262.21% | 128.75% | 366.09% | 283.91% | 162.83% |
| Repurchase of Common Stock | -87.81% | -131.43% | -125.93% | -128.38% | -166.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 376.23% | 127.60% | 720.47% | 443.67% | 160.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 797.70% | -73.45% | 612.34% | 64.70% | -172.81% |